Jean-Yves Douillard.

Jean-Yves Douillard, M.D ., Ph.D., Kelly S. Oliner, Ph.D., Salvatore Siena, M.D., Josep Tabernero, M.D., Ronald Burkes, M.D., Mario Barugel, M.D., Yves Humblet, M.D., Ph.D., Gyorgy Bodoky, M.D., Ph.D., David Cunningham, M.D., Jacek Jassem, M.D., Ph.D., Fernando Rivera, M.D., Ph.D.D., Ph.D., Paul Ruff, M.D.D.D., Jean Luc Canon, M.D., Mark Rother, M.D., Richard Williams, M.B., B.S., Ph.D., Alan Rong, Ph.D., Jeffrey Wiezorek, M.D., Roger Sidhu, M.D., and Scott D. Patterson, Ph.D.1-4 Specifically, individuals with KRAS mutations in exon 2 do not have a response to anti-EGFR therapy and could have inferior outcomes if this therapy is coupled with an oxaliplatin-containing chemotherapy regimen.

5. Michigan scientists want to explore all sorts of stem cells to look for treatments or cures. However they currently lack an integral tool: the capability to develop their own embryonic stem cell lines. Most Michigan scientists, along with many Michigan residents suffering from debilitating diseases, want present state regulation to be transformed. If the Proposal 2 ballot initiative passes, regulations would change to allow Michigan scientists to do what they presently cannot: develop brand-new embryonic stem cell lines using early-stage embryos from fertilization clinics that would otherwise become discarded.